Golden L. Peters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Golden L. Peters has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abigail Elmes-Patel
Department of Pharmacy Practice University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication - Alexander F. Infante
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication - Angela Kerins
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication Anwar Alharir
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication- Cecilia Nyman
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication David E. Zimmerman
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication
Latest Publications
- 3 June 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (6) , 500-510
Pharmacists' contributions to the management of opioid use disorder
Clinicians continue to work toward ending the opioid‐related overdose and death epidemic in the United States. Opioid use disorder (OUD) is a chronic and relapsing disease characterized by an overpowering desire to use opioids despite serious adverse effects, impairment, or distress. Management of OUD requires team‐based care. Pharmacists are uniquely positioned to contribute to the management of OUD in all stages and have demonstrated positive outcomes. Pharmacists are the most accessible health care professionals in community settings, and they practice in all settings across the health care continuum. However, opportunities exist to bridge the disparity between the demand for treatment and its availability. Regulatory barriers limit innovation and expansion of pharmacy services. This white paper describes pharmacists' contributions to the management of OUD and identifies opportunities to leverage pharmacists within the health care landscape to improve patient outcomes.
- 3 June 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (6) , 500-510
Pharmacists' contributions to the management of opioid use disorder
Clinicians continue to work toward ending the opioid‐related overdose and death epidemic in the United States. Opioid use disorder (OUD) is a chronic and relapsing disease characterized by an overpowering desire to use opioids despite serious adverse effects, impairment, or distress. Management of OUD requires team‐based care. Pharmacists are uniquely positioned to contribute to the management of OUD in all stages and have demonstrated positive outcomes. Pharmacists are the most accessible health care professionals in community settings, and they practice in all settings across the health care continuum. However, opportunities exist to bridge the disparity between the demand for treatment and its availability. Regulatory barriers limit innovation and expansion of pharmacy services. This white paper describes pharmacists' contributions to the management of OUD and identifies opportunities to leverage pharmacists within the health care landscape to improve patient outcomes.
- 8 February 2021
- Published by Taylor & Francis in Pain Management
- Vol. 11 (3) , 259-266
Rimegepant: Acute Treatment for Migraine Headaches
Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment opt... Lay abstract Migraine headache treatment is quickly evolving. There have been three new fast-acting treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new treatment options to pr...
- 8 February 2021
- Published by Taylor & Francis in Pain Management
- Vol. 11 (3) , 259-266
Rimegepant: Acute Treatment for Migraine Headaches
Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment opt... Lay abstract Migraine headache treatment is quickly evolving. There have been three new fast-acting treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new treatment options to pr...